## **Clark Donald Russell**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7120697/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ, The, 2020, 369, m1985.	3.0	2,474
2	Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet, The, 2020, 395, 473-475.	6.3	1,644
3	Genetic mechanisms of critical illness in COVID-19. Nature, 2021, 591, 92-98.	13.7	1,014
4	Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ, The, 2020, 370, m3339.	3.0	779
5	Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia. Clinical Infectious Diseases, 2016, 62, 817-823.	2.9	322
6	The Human Immune Response to Respiratory Syncytial Virus Infection. Clinical Microbiology Reviews, 2017, 30, 481-502.	5.7	264
7	Tissue-Specific Immunopathology in Fatal COVID-19. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 192-201.	2.5	243
8	Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe, The, 2021, 2, e354-e365.	3.4	216
9	Whole-genome sequencing reveals host factors underlying critical COVID-19. Nature, 2022, 607, 97-103.	13.7	174
10	Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. Science Immunology, 2021, 6, .	5.6	161
11	Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. Lancet Respiratory Medicine,the, 2021, 9, 349-359.	5.2	161
12	The utility of peripheral blood leucocyte ratios as biomarkers in infectious diseases: A systematic review and meta-analysis. Journal of Infection, 2019, 78, 339-348.	1.7	131
13	A prenylated dsRNA sensor protects against severe COVID-19. Science, 2021, 374, eabj3624.	6.0	124
14	Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. Lancet, The, 2021, 398, 223-237.	6.3	110
15	The role of proâ€resolution lipid mediators in infectious disease. Immunology, 2014, 141, 166-173.	2.0	103
16	Development of two real-time multiplex PCR assays for the detection and quantification of eight key bacterial pathogens in lower respiratory tract infections. Clinical Microbiology and Infection, 2015, 21, 788.e1-788.e13.	2.8	90
17	Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. Lancet Respiratory Medicine,the, 2021, 9, 773-785.	5.2	78
18	Twelve tips for teachers to encourage student engagement in academic medicine. Medical Teacher, 2013, 35, 549-554.	1.0	51

CLARK DONALD RUSSELL

#	Article	IF	CITATIONS
19	What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? A harmonised, global longitudinal observational study protocol. BMJ Open, 2021, 11, e043887.	0.8	51
20	Non-tuberculous mycobacteria: a retrospective review of Scottish isolates from 2000 to 2010: TableÂ1. Thorax, 2014, 69, 593-595.	2.7	44
21	Microbiological characteristics of acute osteoarticular infections in children. Journal of Medical Microbiology, 2015, 64, 446-453.	0.7	44
22	Global outbreak research: harmony not hegemony. Lancet Infectious Diseases, The, 2020, 20, 770-772.	4.6	40
23	Treatable traits and therapeutic targets: Goals for systems biology in infectious disease. Current Opinion in Systems Biology, 2017, 2, 140-146.	1.3	37
24	Diagnosis and features of hospital-acquired pneumonia: a retrospective cohort study. Journal of Hospital Infection, 2016, 92, 273-279.	1.4	35
25	The Role of Interferon-λ Locus Polymorphisms in Hepatitis C and Other Infectious Diseases. Journal of Innate Immunity, 2015, 7, 231-242.	1.8	34
26	Dynamic data-driven meta-analysis for prioritisation of host genes implicated in COVID-19. Scientific Reports, 2020, 10, 22303.	1.6	31
27	Adjunctive rifampicin may improve outcomes in Staphylococcus aureus bacteraemia: a systematic review. Journal of Medical Microbiology, 2014, 63, 841-848.	0.7	28
28	Tissue Proteomic Analysis Identifies Mechanisms and Stages of Immunopathology in Fatal COVID-19. American Journal of Respiratory Cell and Molecular Biology, 2022, 66, 196-205.	1.4	26
29	Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. Thorax, 2022, 77, 606-615.	2.7	24
30	The index case of SARS-CoV-2 in Scotland. Journal of Infection, 2020, 81, 147-178.	1.7	22
31	Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study. The Lancet Digital Health, 2022, 4, e220-e234.	5.9	20
32	An RNA-dependent mechanism for transient expression of bacterial translocation filaments. Nucleic Acids Research, 2018, 46, 3366-3381.	6.5	19
33	UK medical students, academia, and the financial crisis. Lancet, The, 2013, 381, 2165.	6.3	17
34	Enhanced surveillance of Staphylococcus aureus bacteraemia to identify targets for infection prevention. Journal of Hospital Infection, 2016, 93, 169-174.	1.4	12
35	Distinct clinical symptom patterns in patients hospitalised with COVID-19 in an analysis of 59,011 patients in the ISARIC-4C study. Scientific Reports, 2022, 12, 6843.	1.6	12
36	Perceived barriers to research in undergraduate medicine. Medical Teacher, 2012, 34, 777-778.	1.0	11

CLARK DONALD RUSSELL

#	Article	IF	CITATIONS
37	Healthcare workers' decision-making about transmission-based infection control precautions is improved by a guidance summary card. Journal of Hospital Infection, 2015, 90, 235-239.	1.4	11
38	Interferon Lambda Genetic Polymorphisms and Viral Infection: The Tip of the Iceberg?. DNA and Cell Biology, 2014, 33, 60-63.	0.9	10
39	Developing Novel Host-Based Therapies Targeting Microbicidal Responses in Macrophages and Neutrophils to Combat Bacterial Antimicrobial Resistance. Frontiers in Immunology, 2020, 11, 786.	2.2	10
40	Vitamin D insufficiency in COVID-19 and influenza A, and critical illness survivors: a cross-sectional study. BMJ Open, 2021, 11, e055435.	0.8	10
41	Intestinal Protein Characterisation of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in Inflammatory Bowel Disease (IBD) and Fatal COVID-19 Infection. Inflammation, 2022, 45, 567-572.	1.7	10
42	Procalcitonin Is Not a Reliable Biomarker of Bacterial Coinfection in People With Coronavirus Disease 2019 Undergoing Microbiological Investigation at the Time of Hospital Admission. Open Forum Infectious Diseases, 2022, 9, ofac179.	0.4	10
43	Eradicating Infectious Disease: Can We and Should We?. Frontiers in Immunology, 2011, 2, 53.	2.2	9
44	Cyclosporine has a potential role in the treatment of SARS. Journal of Infection, 2013, 67, 84-85.	1.7	9
45	Exogenous steroid-induced hypoadrenalism in a person living with HIV caused by a drug–drug interaction between cobicistat and intrabursal triamcinolone. BMJ Case Reports, 2018, 11, e226912.	0.2	7
46	Challenges in the Diagnosis of Leptospirosis Outwith Endemic Settings: A Scottish Single Centre Experience. Journal of the Royal College of Physicians of Edinburgh, The, 2018, 48, 9-15.	0.2	7
47	Outcomes, Microbiology and Antimicrobial Usage in Pressure Ulcer-Related Pelvic Osteomyelitis: Messages for Clinical Practice. Journal of Bone and Joint Infection, 2020, 5, 67-75.	0.6	7
48	Histological Evidence of Pulmonary Microthrombosis and Vasculitis in Life-Threatening Respiratory Virus Diseases. Open Forum Infectious Diseases, 2021, 8, ofaa640.	0.4	6
49	Tractable targets for meropenem-sparing antimicrobial stewardship interventions. JAC-Antimicrobial Resistance, 2019, 1, dlz042.	0.9	5
50	Evaluating the national student association of medical research. Medical Education, 2014, 48, 1105-1106.	1.1	4
51	Infected deep vein thrombophlebitis in people who inject drugs: missed opportunities and potential for alternative antimicrobial approaches. Infection, 2021, , 1.	2.3	4
52	Heterogeneity in <i>Staphylococcus aureus</i> Bacteraemia Clinical Trials Complicates Interpretation of Findings. Journal of Infectious Diseases, 2022, 226, 723-728.	1.9	4
53	Streptococcus vaccination and MRSA. Lancet Infectious Diseases, The, 2012, 12, 586.	4.6	3
54	Stratified infection medicine: a call to arms. Lancet Infectious Diseases, The, 2014, 14, 451.	4.6	2

#	Article	IF	CITATIONS
55	Challenges of Interpreting Cytomegalovirus DNAemia and Its Potential Association With Chronic Lung Disease in Children and Adolescents With Perinatally Acquired Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 2020, 70, 989-990.	2.9	2
56	Comment on: Doxycycline in UK guidelines for hospital-acquired pneumonia: where is the evidence base?. Journal of Antimicrobial Chemotherapy, 2019, 74, 1765-1766.	1.3	2
57	Successful reintroduction of tumour necrosis factor-alpha inhibition after treatment of disseminated Lyme borreliosis. Journal of the Royal College of Physicians of Edinburgh, The, 2019, 49, 122-124.	0.2	2
58	Is the Thoracic Revised Cardiac Risk Index Really a Useful Scoring System?. Annals of Thoracic Surgery, 2014, 98, 1525.	0.7	1
59	Preventing peripheral venous catheter-related Staphylococcus aureus bacteraemia. British Journal of Hospital Medicine (London, England: 2005), 2017, 78, 666-667.	0.2	1
60	Exploiting an early immunological window of opportunity in COVID-19. Lancet Respiratory Medicine,the, 2021, 9, 811-812.	5.2	1
61	Phenotypic and molecular detection methods for carbapenemase-producing organisms and their clinical significance at two Scottish tertiary care hospitals. Journal of Medical Microbiology, 2019, 68, 560-565.	0.7	1
62	Reply to Zelyas and Robinson. Clinical Infectious Diseases, 2016, 63, 142.2-143.	2.9	0
63	A Subgroup of Patients With Hospital-acquired Pneumonia Do Not Require Broad-spectrum Gram-negative Antimicrobial Coverage. Clinical Infectious Diseases, 2020, 71, e710-e713.	2.9	0
64	Defining resistance and tolerance traits in Covid-19: towards a stratified medicine approach. QJM - Monthly Journal of the Association of Physicians, 0, , .	0.2	0